{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:14:18Z","timestamp":1791476058437,"version":"4.3.4"},"reference-count":176,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine &amp; Growth Factor Reviews"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.cytogfr.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:30:20Z","timestamp":1721781020000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Targeting cytokines in psoriatic arthritis"],"prefix":"10.1016","volume":"78","author":[{"given":"Laura","family":"Neurath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sticherling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Fagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"14","key":"10.1016\/j.cytogfr.2024.06.001_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411662","article-title":"Inflammatory cytokines in psoriatic arthritis: understanding pathogenesis and implications for treatment","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.06.001_bib4","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib5","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13075-018-1691-z","article-title":"Simultaneous quantification of bone erosions and enthesiophytes in the joints of patients with psoriasis or psoriatic arthritis \u2013 effects of age and disease duration","volume":"20","author":"Simon","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib6","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/annrheumdis-2014-206347","article-title":"Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis","volume":"75","author":"Simon","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.clinthera.2023.07.003","article-title":"Genetic studies investigating susceptibility to psoriatic arthritis: a narrative review","volume":"45","author":"Soomro","year":"2023","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/ard-2022-223389","article-title":"Alterations in the cutaneous microbiome of patients with psoriasis and psoriatic arthritis reveal similarities between non-lesional and lesional skin","volume":"82","author":"Boix-Amoros","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/PTT.S328439","article-title":"The skin microbiome and its role in psoriasis: a review","volume":"13","author":"Celoria","year":"2023","journal-title":"Psoriasis"},{"issue":"20","key":"10.1016\/j.cytogfr.2024.06.001_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010990","article-title":"Blood-based immune profiling combined with machine learning discriminates psoriatic arthritis from psoriasis patients","volume":"22","author":"Mulder","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-023-01072-1","article-title":"Biologics in prevention of psoriasis to psoriatic arthritis transition: the need of prospective analyses and stratification according to time-related risk factors","volume":"14","author":"Errichetti","year":"2024","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.12.013","article-title":"Time to transition from psoriasis to psoriatic arthritis: a population-based study","volume":"52","author":"Karmacharya","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib14","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.06.001_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102140","article-title":"Biologic disease-modifying antirheumatic drugs for preventing radiographic progression in psoriatic arthritis: a systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr. Rheumatol. Rep."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib17","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/art.39973","article-title":"The development of psoriatic arthritis in patients with psoriasis is preceded by a period of nonspecific musculoskeletal symptoms: a prospective cohort study","volume":"69","author":"Eder","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001067","article-title":"Transition phase towards psoriatic arthritis: clinical and ultrasonographic characterisation of psoriatic arthralgia","volume":"5","author":"Zabotti","year":"2019","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.06.001_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24055006","article-title":"Evaluation of the synovial effects of biological and targeted synthetic DMARDs in patients with psoriatic arthritis: a systematic literature review and meta-analysis","volume":"24","author":"Ciliento","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003143","article-title":"Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce","volume":"9","author":"De Marco","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae172","article-title":"Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel","author":"Coates","year":"2024","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/acr.25230","article-title":"Comorbidities in early psoriatic arthritis: data from the metabolic disturbances in psoriatic arthritis cohort study","volume":"76","author":"Ishchenko","year":"2024","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib23","first-page":"426","article-title":"Management of psoriatic arthritis in patients with comorbidities: an updated literature review informing the 2021 GRAPPA treatment recommendations","volume":"50","author":"Campanholo","year":"2023","journal-title":"J. Rheumatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clinthera.2023.01.006","article-title":"Comorbidities in psoriatic arthritis: a narrative review","volume":"45","author":"Panagiotopoulos","year":"2023","journal-title":"Clin. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib25","article-title":"The impact of comorbidities on interleukin-17 inhibitor therapy in psoriatic arthritis: a Danish population-based cohort study","volume":"7","author":"Petersen","year":"2023","journal-title":"Rheumatol. Adv. Pract."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib26","first-page":"1815","article-title":"Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations","volume":"41","author":"Scriffignano","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002533","article-title":"Impact of psoriatic arthritis and comorbidities on ustekinumab outcomes in psoriasis: a retrospective, observational BADBIR cohort study","volume":"9","author":"Tillett","year":"2023","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib28","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/rheumatology\/keac403","article-title":"Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization","volume":"62","author":"Zhao","year":"2023","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00296-020-04775-2","article-title":"Comorbidities in psoriatic arthritis: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2021","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib30","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/ar1864","article-title":"Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis","volume":"8","author":"Jongbloed","year":"2006","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.06.001_bib31","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1111\/j.1538-7836.2010.03983.x","article-title":"Immature myeloid dendritic cells capture and remove activated platelets from preformed aggregates","volume":"8","author":"Maitre","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib32","first-page":"374","article-title":"Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity?","volume":"34","author":"Candia","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib33","doi-asserted-by":"crossref","first-page":"1346757","DOI":"10.3389\/fmed.2024.1346757","article-title":"From PsO to PsA: the role of T(RM) and Tregs in psoriatic disease, a systematic review of the literature","volume":"11","author":"Lobao","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib34","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320916014","article-title":"The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2","volume":"11","author":"Wang","year":"2020","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib35","doi-asserted-by":"crossref","first-page":"20675","DOI":"10.1038\/s41598-022-24924-w","article-title":"Regulatory T cells in psoriatic arthritis: an IL-17A-producing, Foxp3(int)CD161 + RORgammat + ICOS + phenotype, that associates with the presence of ADAMTSL5 autoantibodies","volume":"12","author":"Pouw","year":"2022","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.06.001_bib36","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib37","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.06.001_bib38","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.39261","article-title":"Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib39","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.4049\/jimmunol.1700596","article-title":"Cutting edge: homeostasis of innate lymphoid cells is imbalanced in psoriatic arthritis","volume":"200","author":"Soare","year":"2018","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076292","article-title":"Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis","volume":"8","author":"Tang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib41","article-title":"Translational research studies unraveling the origins of psoriatic arthritis: moving beyond skin and joints","volume":"8","author":"Bolt","year":"2021","journal-title":"Front. Med."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.06.001_bib42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nri2358","article-title":"Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases","volume":"8","author":"Gilliet","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0198-8859(99)00034-8","article-title":"Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis","volume":"60","author":"Tassiulas","year":"1999","journal-title":"Hum. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47310-5","article-title":"Increased frequency of activated CD8(+) T cell effectors in patients with psoriatic arthritis","volume":"9","author":"Diani","year":"2019","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.06.001_bib45","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1002\/art.41652","article-title":"Tissue-resident memory CD8+ T cells from skin differentiate psoriatic arthritis from psoriasis","volume":"73","author":"Leijten","year":"2021","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/art.41156","article-title":"Polyfunctional, proinflammatory, tissue-resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis","volume":"72","author":"Steel","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.06.001_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112514","article-title":"Psoriatic and rheumatoid arthritis joints differ in the composition of CD8+ tissue-resident memory T cell subsets","volume":"42","author":"Povoleri","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202149702","article-title":"CCR4(+) CD8(+) T cells clonally expand to differentiated effectors in murine psoriasis and in human psoriatic arthritis","volume":"53","author":"Montico","year":"2023","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.cytogfr.2024.06.001_bib49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1136\/annrheumdis-2020-218186","article-title":"IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors","volume":"80","author":"Nerviani","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.autrev.2014.11.012","article-title":"T cell responses in psoriasis and psoriatic arthritis","volume":"14","author":"Diani","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.672515","article-title":"From bed to bench and back: TNF-alpha, IL-23\/IL-17A, and JAK-dependent inflammation in the pathogenesis of psoriatic synovitis","volume":"12","author":"Silvagni","year":"2021","journal-title":"Front. Pharm."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib52","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102973","article-title":"Regulatory T cells enhance Th17 migration in psoriatic arthritis which is reversed by anti-TNF","volume":"24","author":"Nguyen","year":"2021","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib54","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/rheumatology\/kead284","article-title":"Predictors of DAPSA28 remission in patients with psoriatic arthritis initiating a first TNF inhibitor: results from 13 European registries","volume":"63","author":"Linde","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib55","doi-asserted-by":"crossref","unstructured":"L.M. Ornbjerg, K. Rugbjerg, S. Georgiadis, S.H. Rasmussen, L. Jacobsson, A.G. Loft, F. Iannone, K.M. Fagerli, J. Vencovsky, M.J. Santos, B. Moller, M. Pombo-Suarez, Z. Rotar, B. Gudbjornsson, A. Cefle, K. Eklund, C. Codreanu, G. Jones, M. van der Sande, J.K. Wallman, M. Sebastiani, B. Michelsen, J. Zavada, M.J. Nissen, C. Sanchez-Piedra, M. Tomsic, T.J. Love, H. Relas, C. Mogosan, M.L. Hetland, M. Ostergaard, Patient-reported outcomes and PRO remission rates in 12,262 biologic-naive patients with psoriatic arthritis treated with TNF-inhibitors in routine care, J. Rheumatol., 2024.","DOI":"10.3899\/jrheum.2023-0764"},{"issue":"8","key":"10.1016\/j.cytogfr.2024.06.001_bib56","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/17512433.2017.1329009","article-title":"Tumor necrosis factor inhibitors in psoriatic arthritis","volume":"10","author":"Mantravadi","year":"2017","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib57","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X231179524","article-title":"Effects of TNF-alpha inhibition versus secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis","volume":"15","author":"Elliott","year":"2023","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002681","article-title":"Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS)","volume":"8","author":"Pina Vegas","year":"2022","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.06.001_bib59","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1056\/NEJMra1909094","article-title":"Reframing immune-mediated inflammatory diseases through signature cytokine hubs","volume":"385","author":"Schett","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108513","article-title":"Psoriatic arthritis under the influence of IFNgamma","volume":"218","author":"Dai","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib61","doi-asserted-by":"crossref","first-page":"13466","DOI":"10.1038\/ncomms13466","article-title":"IL-12 protects from psoriasiform skin inflammation","volume":"7","author":"Kulig","year":"2016","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.cytogfr.2024.06.001_bib62","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/annrheumdis-2018-214944","article-title":"Identification of myeloid cells in the human enthesis as the main source of local IL-23 production","volume":"78","author":"Bridgewood","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.cytogfr.2024.06.001_bib63","first-page":"S12","article-title":"The role of IL-23 and the use of IL-23 inhibitors in psoriatic arthritis","volume":"20 Suppl. 1","author":"Fragoulis","year":"2022","journal-title":"Musculoskelet. Care"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154855","article-title":"Functional significance of MAIT cells in psoriatic arthritis","volume":"125","author":"Raychaudhuri","year":"2020","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.06.001_bib65","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib66","doi-asserted-by":"crossref","first-page":"8259","DOI":"10.1038\/s41598-020-65269-6","article-title":"Skin expression of IL-23 drives the development of psoriasis and psoriatic arthritis in mice","volume":"10","author":"Chen","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib67","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s12026-023-09366-4","article-title":"Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials","volume":"71","author":"Huang","year":"2023","journal-title":"Immunol. Res."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.06.001_bib68","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/acr.22645","article-title":"Maintenance of clinical efficacy and radiographic benefit through two years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial","volume":"67","author":"Kavanaugh","year":"2015","journal-title":"Arthritis Care Res."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib69","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"9894","key":"10.1016\/j.cytogfr.2024.06.001_bib70","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib71","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s40744-024-00644-7","article-title":"Comparing efficacy of guselkumab versus ustekinumab in patients with psoriatic arthritis: an adjusted comparison using individual patient data from the DISCOVER and PSUMMIT trials","volume":"11","author":"Thilakarathne","year":"2024","journal-title":"Rheumatol. Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib72","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/annrheumdis-2021-220991","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)","volume":"81","author":"Coates","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.06.001_bib73","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1007\/s12325-022-02269-0","article-title":"The effect of guselkumab on general health state in biologic-naive patients with active psoriatic arthritis through week 52 of the phase 3, randomized, placebo-controlled DISCOVER-2 trial","volume":"39","author":"Curtis","year":"2022","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib74","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"McInnes","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002195","article-title":"Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies","volume":"8","author":"Ritchlin","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib76","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001217","article-title":"Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study","volume":"6","author":"Mease","year":"2020","journal-title":"RMD Open"},{"issue":"10230","key":"10.1016\/j.cytogfr.2024.06.001_bib77","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.cytogfr.2024.06.001_bib78","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib79","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","article-title":"Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis","volume":"62","author":"Coates","year":"2023","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001679","article-title":"Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials","volume":"7","author":"Sweet","year":"2021","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib81","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib82","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"Ostor","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib83","doi-asserted-by":"crossref","first-page":"1286251","DOI":"10.3389\/fimmu.2023.1286251","article-title":"The optimal use of tildrakizumab in the elderly via improvement of Treg function and its preventive effect of psoriatic arthritis","volume":"14","author":"Fukasawa","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib84","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040526","article-title":"A real-life study on the use of tildrakizumab in psoriatic patients","volume":"16","author":"Campione","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib85","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/12034754231155889","article-title":"Tildrakizumab in complex psoriatic patients: an experience in Emilia-Romagna (Italy)","volume":"27","author":"Bardazzi","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib86","doi-asserted-by":"crossref","first-page":"2133531","DOI":"10.1080\/09546634.2022.2133531","article-title":"Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis","volume":"34","author":"Elgaard","year":"2023","journal-title":"J. Dermatol. Treat."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib87","article-title":"Tildrakizumab: successful response in two patients with psoriatic arthritis","volume":"12","author":"Buononato","year":"2022","journal-title":"Dermatol. Pract. Concept."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib88","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000519924","article-title":"Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients","volume":"238","author":"Drerup","year":"2022","journal-title":"Dermatology"},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib89","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib90","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13216","article-title":"Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment","volume":"33","author":"Ismail","year":"2020","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib91","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib92","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"issue":"10","key":"10.1016\/j.cytogfr.2024.06.001_bib93","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/art.27622","article-title":"Role of Th17 cells in human autoimmune arthritis","volume":"62","author":"Leipe","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib94","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3899\/jrheum.150636","article-title":"Ex vivo signaling protein mapping in T lymphocytes in the psoriatic arthritis joints","volume":"93","author":"Fiocco","year":"2015","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib95","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fimmu.2018.00606","article-title":"Distinct in vitro T-helper 17 differentiation capacity of peripheral naive T cells in rheumatoid and psoriatic arthritis","volume":"9","author":"Baricza","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11926-021-01005-x","article-title":"Drivers of inflammation in psoriatic arthritis: the old and the new","volume":"23","author":"O'Brien-Gore","year":"2021","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib97","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13075-023-03034-6","article-title":"Cutaneous lesions in psoriatic arthritis are enriched in chemokine transcriptomic pathways","volume":"25","author":"Johnsson","year":"2023","journal-title":"Arthritis Res. Ther."},{"issue":"11","key":"10.1016\/j.cytogfr.2024.06.001_bib98","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1002\/art.38816","article-title":"Regulation of cytokine polarization and T cell recruitment to inflamed paws in mouse collagen-induced arthritis by the chemokine receptor CXCR6","volume":"66","author":"Slauenwhite","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib99","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib100","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","year":"2015","journal-title":"Periodontol 2000"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib101","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13075-019-2055-z","article-title":"Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies","volume":"21","author":"Coates","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib102","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40744-022-00445-w","article-title":"Responses to ixekizumab in male and female patients with psoriatic arthritis: results from two randomized, phase 3 clinical trials","volume":"9","author":"Eder","year":"2022","journal-title":"Rheumatol. Ther."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib103","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000692","volume":"4","author":"Nash","year":"2018","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib104","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3899\/jrheum.170429","article-title":"Efficacy and safety of ixekizumab in patients with active psoriatic arthritis: 52-week results from a phase III study (SPIRIT-P1)","volume":"45","author":"van der Heijde","year":"2018","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152388","article-title":"Ornbjerg, Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice","volume":"65","author":"Christiansen","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib106","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/RHU.0000000000001302","article-title":"Secukinumab efficacy in psoriatic arthritis: machine learning and meta-analysis of four phase 3 trials","volume":"27","author":"Gottlieb","year":"2021","journal-title":"J. Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib107","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000567","article-title":"Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naive patients with active psoriatic arthritis (PsA): results from SPIRIT-P1","volume":"3","author":"Coates","year":"2017","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib108","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10086","key":"10.1016\/j.cytogfr.2024.06.001_bib109","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib110","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1093\/rheumatology\/keaa824","article-title":"Improvement from ixekizumab treatment in patients with psoriatic arthritis who have had an inadequate response to one or two TNF inhibitors","volume":"60","author":"Kirkham","year":"2021","journal-title":"Rheumatology"},{"issue":"14","key":"10.1016\/j.cytogfr.2024.06.001_bib111","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9999","key":"10.1016\/j.cytogfr.2024.06.001_bib112","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib113","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.06.001_bib114","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.40581","article-title":"Brief report: interleukin-17 blockade with secukinumab in peripheral spondyloarthritis impacts synovial immunopathology without compromising systemic immune responses","volume":"70","author":"van Mens","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib115","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/eji.202048690","article-title":"TLR7 endogenous ligands remodel glycolytic macrophages and trigger skin-to-joint crosstalk in psoriatic arthritis","volume":"51","author":"Van Raemdonck","year":"2021","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib116","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib117","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"10370","key":"10.1016\/j.cytogfr.2024.06.001_bib118","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-alpha inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cytogfr.2024.06.001_bib119","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2017.53.5.2613690","article-title":"Brodalumab: the first anti-IL-17 receptor agent for psoriasis","volume":"53","author":"Puig","year":"2017","journal-title":"Drugs Today"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"21","key":"10.1016\/j.cytogfr.2024.06.001_bib121","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.cell.2022.09.023","article-title":"The JAK-STAT pathway at 30: much learned, much more to do","volume":"185","author":"Philips","year":"2022","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib122","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jaci.2021.08.004","article-title":"JAK-STAT signaling in human disease: from genetic syndromes to clinical inhibition","volume":"148","author":"Luo","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib123","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"22","key":"10.1016\/j.cytogfr.2024.06.001_bib125","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1242\/dev.078055","article-title":"Glypicans regulate JAK\/STAT signaling and distribution of the Unpaired morphogen","volume":"139","author":"Hayashi","year":"2012","journal-title":"Development"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib126","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a011205","article-title":"The Jak\/STAT pathway","volume":"4","author":"Harrison","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.06.001_bib127","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib128","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak-STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib129","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/14728214.2023.2186399","article-title":"Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials","volume":"28","author":"Neurath","year":"2023","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib130","doi-asserted-by":"crossref","unstructured":"H. Bachelez, C.E.M. Griffiths, K.A. Papp, S. Hall, J.F. Merola, S.R. Feldman, M. Khraishi, H. Tan, L. Fallon, J.C. Cappelleri, A.G. Bushmakin, P. Young, Tofacitinib efficacy, patient-reported outcomes and safety in patients with psoriasis and a medical history of psoriatic arthritis: pooled analysis of two Phase III studies, J. Eur. Acad. Dermatol. Venereol., 2024.","DOI":"10.1111\/jdv.19701"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib131","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-024-06930-7","article-title":"Real-world evaluation of persistence, effectiveness and usage patterns of tofacitinib in treatment of psoriatic arthritis in Australia","author":"Littlejohn","year":"2024","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib132","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40744-023-00631-4","article-title":"Effectiveness of tofacitinib in patients initiating therapy for psoriatic arthritis: results from the CorEvitas psoriatic arthritis\/spondyloarthritis registry","volume":"11","author":"Mease","year":"2024","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib133","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib134","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib135","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2665-9913(20)30339-8","article-title":"Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance","volume":"3","author":"Nash","year":"2021","journal-title":"Lancet Rheumatol."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib136","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40744-020-00209-4","article-title":"Safety and efficacy of tofacitinib in patients with active psoriatic arthritis: interim analysis of OPAL balance, an open-label, long-term extension study","volume":"7","author":"Nash","year":"2020","journal-title":"Rheumatol. Ther."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.06.001_bib137","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/jdv.16433","article-title":"Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies","volume":"34","author":"Merola","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib138","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003550","article-title":"Pharmacodynamic effects of filgotinib treatment driving clinical improvement in patients with active psoriatic arthritis enrolled in the EQUATOR trial","volume":"9","author":"Chandran","year":"2023","journal-title":"RMD Open"},{"issue":"7","key":"10.1016\/j.cytogfr.2024.06.001_bib139","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1093\/rheumatology\/kez408","article-title":"Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR)","volume":"59","author":"Orbai","year":"2020","journal-title":"Rheumatology"},{"issue":"10162","key":"10.1016\/j.cytogfr.2024.06.001_bib140","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.cytogfr.2024.06.001_bib141","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2217\/imt-2021-0130","article-title":"Use of upadacitinib in the treatment of psoriatic arthritis","volume":"13","author":"Ross","year":"2021","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib142","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials","volume":"9","author":"Burmester","year":"2022","journal-title":"Rheumatol. Ther."},{"issue":"13","key":"10.1016\/j.cytogfr.2024.06.001_bib143","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","article-title":"Trial of upadacitinib and adalimumab for psoriatic arthritis","volume":"384","author":"McInnes","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib144","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001838","article-title":"Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study","volume":"7","author":"McInnes","year":"2021","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.cytogfr.2024.06.001_bib145","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib146","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keae057","article-title":"Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2","author":"Cantini","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib147","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2023-2-7","article-title":"Deucravacitinib for the treatment of psoriatic arthritis: the evidence so far","volume":"12","author":"Martins","year":"2023","journal-title":"Drugs Context"},{"issue":"8","key":"10.1016\/j.cytogfr.2024.06.001_bib148","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and Safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib149","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40744-023-00621-6","article-title":"Malignancy in the upadacitinib clinical trials for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis","volume":"11","author":"Rubbert-Roth","year":"2024","journal-title":"Rheumatol. Ther."},{"issue":"23","key":"10.1016\/j.cytogfr.2024.06.001_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312878","article-title":"Phosphodiesterase-4 inhibition reduces cutaneous inflammation and IL-1beta expression in a psoriasiform mouse model but does not inhibit inflammasome activation","volume":"22","author":"Meier-Schiesser","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib152","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1185\/03007995.2016.1140026","article-title":"An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naive patients with psoriatic arthritis","volume":"32","author":"Betts","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib153","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"Randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib154","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib155","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40744-024-00641-w","article-title":"Use of apremilast to achieve psoriatic arthritis treatment goals and satisfaction at 1 year in the Canadian real-world APPRAISE study","volume":"11","author":"Chandran","year":"2024","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib156","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.reuma.2023.06.007","article-title":"Real-world apremilast use in biologic-naive psoriatic arthritis patients. Data from Spanish clinical practice","volume":"20","author":"Gratacos-Masmitja","year":"2024","journal-title":"Reumatol. Clin. (Engl. Ed.)"},{"issue":"9","key":"10.1016\/j.cytogfr.2024.06.001_bib157","first-page":"1162","article-title":"EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis","volume":"82","author":"Zabotti","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib158","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/annrheumdis-2021-221255","article-title":"Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?","volume":"81","author":"McGonagle","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib159","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2665-9913(23)00034-6","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Singla","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"10.1016\/j.cytogfr.2024.06.001_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063650","article-title":"Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial","volume":"12","author":"Haberman","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib161","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13075-019-1957-0","article-title":"Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study","volume":"21","author":"Kampylafka","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib162","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib163","article-title":"Tolerability and comparative effectiveness of TNF-, IL-17-, and IL-23(p19) inhibitors in psoriatic arthritis: a target trial emulation study","author":"Stisen","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.851892","article-title":"Dawn of precision medicine in psoriatic arthritis","volume":"9","author":"Miyagawa","year":"2022","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib165","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s13075-022-02956-x","article-title":"Four emerging immune cellular blood phenotypes associated with disease duration and activity established in psoriatic arthritis","volume":"24","author":"Skougaard","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.cytogfr.2024.06.001_bib166","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41584-018-0043-3","article-title":"Personalized medicine \u2013 a new reality in psoriatic arthritis?","volume":"14","author":"Al-Mossawi","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"issue":"10235","key":"10.1016\/j.cytogfr.2024.06.001_bib167","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cytogfr.2024.06.001_bib168","article-title":"Efficacy and safety of ixekizumab versus adalimumab in biologic-naive patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomized SPIRIT-H2H trial","volume":"12","author":"Reich","year":"2022","journal-title":"Dermatol. Pract. Concept."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib169","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/ard-2022-222879","article-title":"Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study","volume":"82","author":"Gossec","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.cytogfr.2024.06.001_bib170","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.semarthrit.2018.05.011","article-title":"Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study","volume":"48","author":"Araujo","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105778","article-title":"Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters","volume":"221","author":"Aksu","year":"2024","journal-title":"Antivir. Res."},{"key":"10.1016\/j.cytogfr.2024.06.001_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149401","article-title":"Nanobodies as negative allosteric modulators for human calcium sensing receptor","volume":"695","author":"Cui","year":"2024","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.cytogfr.2024.06.001_bib173","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13568-023-01659-z","article-title":"Nanobodies as potential tools for microbiological testing of live biotherapeutic products","volume":"14","author":"Dorosky","year":"2024","journal-title":"AMB Express"},{"key":"10.1016\/j.cytogfr.2024.06.001_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2023.115995","article-title":"Aptamers for nanobodies: a nontoxic alternative to toxic ochratoxin A in immunoassays","volume":"248","author":"Hou","year":"2024","journal-title":"Biosens. Bioelectron."},{"issue":"Pt 2","key":"10.1016\/j.cytogfr.2024.06.001_bib175","article-title":"Development of nanobodies specific to clumping factors A of Staphylococcus aureus by yeast surface display","volume":"259","author":"Mei","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"6","key":"10.1016\/j.cytogfr.2024.06.001_bib176","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065994","article-title":"Nanobodies: a review of generation, diagnostics and therapeutics","volume":"24","author":"Jin","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["Cytokine &amp; Growth Factor Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012400042X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135961012400042X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T10:57:24Z","timestamp":1723719444000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135961012400042X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":176,"alternative-id":["S135961012400042X"],"URL":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.06.001","relation":{},"ISSN":["1359-6101"],"issn-type":[{"value":"1359-6101","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting cytokines in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Cytokine & Growth Factor Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cytogfr.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}